Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy

BACKGROUND: Approximately 90% of patients with metastatic colorectal cancer fail therapy mainly due to resistance. Taking advantage of currently approved agents for treatment of disease conditions other than cancer for the identification of new adjuvant anticancer therapies is highly encouraged. Pra...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Keilani, Maha S, Alsmadi, Dua H, Darweesh, Ruba S, Alzoubi, Karem H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842772/
https://www.ncbi.nlm.nih.gov/pubmed/29551915
http://dx.doi.org/10.2147/CPAA.S153780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842772/
https://www.ncbi.nlm.nih.gov/pubmed/29551915
http://dx.doi.org/10.2147/CPAA.S153780

Ejemplares similares